EnteroBiotix Raises £19M to Launch Phase 2b Microbiome Trial for Irritable Bowel Syndrome Treatment

Key Takeaways

• EnteroBiotix completed £19M ($25M) funding round to advance full-spectrum microbiome therapy for irritable bowel syndrome
• Phase 2b ‘RISE’ trial will be the largest interventional microbiome study ever conducted in IBS patients
• First patient dosing expected Q2 2026 with topline efficacy results anticipated in H2 2027

---

Glasgow-based EnteroBiotix Limited announced the completion of a £19 million ($25 million) funding round on April 29, 2026, to initiate what will become the largest Phase 2b clinical trial of a full-spectrum microbiome product for irritable bowel syndrome (IBS) treatment.

The biopharmaceutical company, which specializes in developing microbiome therapies for gut health conditions, will use the funding to launch the Phase 2b ‘RISE’ trial. This study represents a significant milestone in microbiome research, positioning itself as the largest interventional clinical trial of its kind in the IBS therapeutic space.

Trial Timeline and Significance

EnteroBiotix expects to dose the first patient in the RISE trial during the second quarter of 2026, with topline efficacy data anticipated in the second half of 2027. The 18-month timeline reflects the comprehensive nature of this interventional study design.

The trial’s scale underscores the growing recognition of microbiome-based therapies as a promising treatment approach for IBS, a condition affecting millions of patients worldwide with limited effective treatment options.

Market Impact and Innovation

This funding milestone positions EnteroBiotix at the forefront of the emerging microbiome therapeutics market. Full-spectrum microbiome products represent an innovative approach that aims to restore the complete gut bacterial ecosystem rather than targeting individual bacterial strains.

The substantial investment reflects growing investor confidence in microbiome-based treatments for gastrointestinal disorders. IBS affects approximately 10-15% of the global population, representing a significant unmet medical need and substantial market opportunity.

Company Background

EnteroBiotix has established itself as a leader in developing best-in-class microbiome therapies specifically focused on gut health applications. The company’s approach involves comprehensive microbiome restoration rather than single-strain probiotic treatments, potentially offering more effective therapeutic outcomes for complex gastrointestinal conditions like IBS.

---

Frequently Asked Questions

What does this funding mean for IBS patients?

This funding enables the largest microbiome trial for IBS, potentially leading to a new treatment option that could be available by 2028 if successful, offering hope for the millions suffering from this condition with limited current therapies.

When will EnteroBiotix’s IBS treatment be available?

The Phase 2b trial begins patient dosing in Q2 2026 with results expected in H2 2027. If successful, the treatment would still need Phase 3 trials and regulatory approval, likely making it available around 2029-2030 at the earliest.

How does full-spectrum microbiome therapy differ from probiotics?

Full-spectrum microbiome therapy aims to restore the complete gut bacterial ecosystem with multiple bacterial strains, while traditional probiotics typically contain only one or a few specific bacterial strains, potentially offering more comprehensive gut health restoration.